LOGIN
Risedronate reduces fracture risk in children with osteogenesis imperfecta
November 2013
Risedronate reduces fracture risk in children with osteogenesis imperfecta
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial
Lancet. 2013 Aug 5. pii: S0140-6736(13)61091-0.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
147 children with osteogenesis imperfecta were randomized to receive risedronate (an oral bisphosphonate) or a placebo in order to evaluate the safety and efficacy of risedronate in this population. The study demonstrated that risedronate was superior in the mean improvement in lumbar spinal BMD- assessed using dual-energy x-ray absorptiometry scanning, and led to a reduced risk of clinical fractu...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.